Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135191 | 1.00 | MAPK7 (0.39) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL20134745 | 0.87 | ADAMTS5 (0.37) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL20134744 | 0.87 | ADAMTS5 (0.37) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL20134770 | 0.87 | CYP1A2 (0.41) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL20134771 | 0.87 | CYP1A2 (0.41) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL29688981 | 0.84 | ADAM17 (0.43) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL20134999 | 0.84 | ADAM17 (0.43) | MAPK7CRBNADAM17ADAMTS5MEN1 | |
| SCHEMBL20135686 | 0.83 | KDM4E (0.44) | MAPK7ADAM17ADAMTS5POLB | |
| SCHEMBL29688837 | 0.83 | KDM4E (0.44) | MAPK7ADAM17ADAMTS5POLB | |
| SCHEMBL20135685 | 0.83 | KDM4E (0.44) | MAPK7ADAM17ADAMTS5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | MAPK7 390/4885CRBN 3363/4885ADAM17 36/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | MAPK7 302/4885CRBN 3419/4885ADAM17 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.